Skip to main content
Top
Published in: Respiratory Research 1/2024

Open Access 01-12-2024 | Research

Smoking status and clinical outcome in idiopathic pulmonary fibrosis: a nationwide study

Authors: Hee-Young Yoon, Hoseob Kim, Yoonjong Bae, Jin Woo Song

Published in: Respiratory Research | Issue 1/2024

Login to get access

Abstract

Background

Smoking status has been linked to the development of idiopathic pulmonary fibrosis (IPF). However, the effect of smoking on the prognosis of patients with IPF is unclear. We aimed to investigate the association between smoking status and all-cause mortality or hospitalisation by using national health claims data.

Methods

IPF cases were defined as people who visited medical institutions between January 2002 and December 2018 with IPF and rare incurable disease exempted calculation codes from the National Health Insurance Database. Total 10,182 patients with available data on smoking status were included in this study. Ever-smoking status was assigned to individuals with a history of smoking ≥ 6 pack-years. The multivariable Cox proportional hazard model was used to evaluate the association between smoking status and prognosis.

Results

In the entire cohort, the mean age was 69.4 years, 73.9% were males, and 45.2% were ever smokers (current smokers: 14.2%; former smokers: 31.0%). Current smokers (hazard ratio [HR]: 0.709; 95% confidence interval [CI]: 0.643–0.782) and former smokers (HR: 0.926; 95% CI: 0.862–0.996) were independently associated with all-cause mortality compared with non-smokers. Current smokers (HR: 0.884; 95% CI: 0.827–0.945) and former smokers (HR: 0.909; 95% CI: 0.862–0.959) were also associated with a reduced risk of all-cause hospitalisation compared with non-smokers. A non-linear association between smoking amount and prognosis was found in a spline HR curve and showed increasing risk below 6 pack-years.

Conclusion

Ever-smoking status may be associated with favourable clinical outcomes in patients with IPF.
Appendix
Available only for authorised users
Literature
1.
go back to reference Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:5.CrossRef Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:5.CrossRef
2.
go back to reference Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208:7.CrossRef Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208:7.CrossRef
3.
go back to reference Kropski JA, Blackwell TS, Loyd JE. The genetic basis of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:6.CrossRef Kropski JA, Blackwell TS, Loyd JE. The genetic basis of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:6.CrossRef
4.
go back to reference Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22:1.CrossRef Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22:1.CrossRef
5.
go back to reference Park Y, Ahn C, Kim T-H. Occupational and environmental risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analyses. Sci Rep. 2021;11:1. Park Y, Ahn C, Kim T-H. Occupational and environmental risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analyses. Sci Rep. 2021;11:1.
6.
go back to reference Lee SH, Yeo Y, Kim TH, Lee HL, Lee JH, Park YB, et al. Korean guidelines for diagnosis and management of interstitial Lung diseases: part 2. Idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul). 2019;82:2. Lee SH, Yeo Y, Kim TH, Lee HL, Lee JH, Park YB, et al. Korean guidelines for diagnosis and management of interstitial Lung diseases: part 2. Idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul). 2019;82:2.
7.
go back to reference Bae W, Lee CH, Lee J, Kim YW, Han K, Choi SM. Impact of smoking on the development of idiopathic pulmonary fibrosis: results from a nationwide population-based cohort study. Thorax. 2022;77:5.CrossRef Bae W, Lee CH, Lee J, Kim YW, Han K, Choi SM. Impact of smoking on the development of idiopathic pulmonary fibrosis: results from a nationwide population-based cohort study. Thorax. 2022;77:5.CrossRef
8.
go back to reference Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155:1.CrossRef Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155:1.CrossRef
9.
go back to reference Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc. 2006;3:4.CrossRef Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc. 2006;3:4.CrossRef
10.
go back to reference Bellou V, Belbasis L, Evangelou E. Tobacco Smoking and Risk for Pulmonary Fibrosis: a prospective cohort study from the UK Biobank. Chest. 2021;160:3.CrossRef Bellou V, Belbasis L, Evangelou E. Tobacco Smoking and Risk for Pulmonary Fibrosis: a prospective cohort study from the UK Biobank. Chest. 2021;160:3.CrossRef
11.
go back to reference Steele MP, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med. 2005;172:9.CrossRef Steele MP, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med. 2005;172:9.CrossRef
12.
go back to reference Moon SW, Kim SY, Chung MP, Yoo H, Jeong SH, Kim DS, et al. Longitudinal changes in clinical features, management, and outcomes of idiopathic pulmonary fibrosis. A Nationwide Cohort Study. Ann Am Thorac Soc. 2021;18:5.CrossRef Moon SW, Kim SY, Chung MP, Yoo H, Jeong SH, Kim DS, et al. Longitudinal changes in clinical features, management, and outcomes of idiopathic pulmonary fibrosis. A Nationwide Cohort Study. Ann Am Thorac Soc. 2021;18:5.CrossRef
13.
go back to reference Hoyer N, Prior TS, Bendstrup E, Wilcke T, Shaker SB. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respir Res. 2019;20:1.CrossRef Hoyer N, Prior TS, Bendstrup E, Wilcke T, Shaker SB. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respir Res. 2019;20:1.CrossRef
14.
go back to reference Wuyts WA, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, et al. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. Respir Res. 2019;20:1.CrossRef Wuyts WA, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, et al. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. Respir Res. 2019;20:1.CrossRef
15.
go back to reference Kishaba T, Nagano H, Nei Y, Yamashiro S. Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis. 2016;8:6.CrossRef Kishaba T, Nagano H, Nei Y, Yamashiro S. Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis. 2016;8:6.CrossRef
16.
go back to reference King TE Jr., Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164:7.CrossRef King TE Jr., Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164:7.CrossRef
17.
go back to reference Antoniou KM, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med. 2008;177:2.CrossRef Antoniou KM, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med. 2008;177:2.CrossRef
18.
go back to reference Kärkkäinen M, Kettunen HP, Nurmi H, Selander T, Purokivi M, Kaarteenaho R. Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. Respir Res. 2017;18:1.CrossRef Kärkkäinen M, Kettunen HP, Nurmi H, Selander T, Purokivi M, Kaarteenaho R. Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. Respir Res. 2017;18:1.CrossRef
19.
go back to reference Zubairi ABS, Ahmad H, Hassan M, Sarwar S, Abbas A, Shahzad T, Irfan M. Clinical characteristics and factors associated with mortality in idiopathic pulmonary fibrosis: an experience from a tertiary care center in Pakistan. Clin Respir J. 2018;12:3.CrossRef Zubairi ABS, Ahmad H, Hassan M, Sarwar S, Abbas A, Shahzad T, Irfan M. Clinical characteristics and factors associated with mortality in idiopathic pulmonary fibrosis: an experience from a tertiary care center in Pakistan. Clin Respir J. 2018;12:3.CrossRef
20.
go back to reference Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37:2.CrossRef Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37:2.CrossRef
21.
go back to reference Platenburg M, van der Vis JJ, Kazemier KM, Grutters JC, van Moorsel CHM. The detrimental effect of quantity of smoking on survival in progressive fibrosing ILD. Respir Med 2022;194. Platenburg M, van der Vis JJ, Kazemier KM, Grutters JC, van Moorsel CHM. The detrimental effect of quantity of smoking on survival in progressive fibrosing ILD. Respir Med 2022;194.
22.
go back to reference Karampitsakos T, Spagnolo P, Mogulkoc N, Wuyts WA, Tomassetti S, Bendstrup E, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: a retrospective multicentre study in Europe. Respirology. 2023;28:1.CrossRef Karampitsakos T, Spagnolo P, Mogulkoc N, Wuyts WA, Tomassetti S, Bendstrup E, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: a retrospective multicentre study in Europe. Respirology. 2023;28:1.CrossRef
23.
go back to reference Tzouvelekis A, Antoniou K, Kreuter M, Evison M, Blum TG, Poletti V, et al. The DIAMORFOSIS (DIAgnosis and management of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Res. 2021;7:1.CrossRef Tzouvelekis A, Antoniou K, Kreuter M, Evison M, Blum TG, Poletti V, et al. The DIAMORFOSIS (DIAgnosis and management of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Res. 2021;7:1.CrossRef
24.
go back to reference Shin DW, Cho B, Guallar E. Korean National Health Insurance Database. JAMA Intern Med. 2016;176:1.CrossRef Shin DW, Cho B, Guallar E. Korean National Health Insurance Database. JAMA Intern Med. 2016;176:1.CrossRef
25.
go back to reference Kim HK, Song SO, Noh J, Jeong I-K, Lee B-W. Data Configuration and Publication Trends for the Korean National Health Insurance and Health Insurance Review & Assessment Database. Diabetes & metabolism journal 2020;44:5. Kim HK, Song SO, Noh J, Jeong I-K, Lee B-W. Data Configuration and Publication Trends for the Korean National Health Insurance and Health Insurance Review & Assessment Database. Diabetes & metabolism journal 2020;44:5.
26.
go back to reference Lim S-S, Lee W, Kim Y-K, Kim J, Park JH, Park BR, Yoon J-H. The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011–2015. Orphanet J Rare Dis. 2019;14:1.CrossRef Lim S-S, Lee W, Kim Y-K, Kim J, Park JH, Park BR, Yoon J-H. The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011–2015. Orphanet J Rare Dis. 2019;14:1.CrossRef
27.
go back to reference Na KH, Kim HJ, Kim KH, Han S, Kim P, Hann HJ, Ahn HS. Prevalence, age at diagnosis, mortality, and cause of death in Retinitis Pigmentosa in Korea-A Nationwide Population-based study. Am J Ophthalmol 2017;176. Na KH, Kim HJ, Kim KH, Han S, Kim P, Hann HJ, Ahn HS. Prevalence, age at diagnosis, mortality, and cause of death in Retinitis Pigmentosa in Korea-A Nationwide Population-based study. Am J Ophthalmol 2017;176.
28.
go back to reference Kramarow EA. Health of former cigarette smokers aged 65 and over: United States, 2018. 2020. Kramarow EA. Health of former cigarette smokers aged 65 and over: United States, 2018. 2020.
29.
go back to reference Becklake MR, Lalloo U. The ‘healthy smoker’: a phenomenon of health selection? Respiration 1990;57:3. Becklake MR, Lalloo U. The ‘healthy smoker’: a phenomenon of health selection? Respiration 1990;57:3.
30.
go back to reference Yu YF, Wu N, Chuang CC, Wang R, Pan X, Benjamin NN, et al. Patterns and Economic Burden of Hospitalizations and exacerbations among patients diagnosed with idiopathic pulmonary fibrosis. J Manag Care Spec Pharm. 2016;22:4. Yu YF, Wu N, Chuang CC, Wang R, Pan X, Benjamin NN, et al. Patterns and Economic Burden of Hospitalizations and exacerbations among patients diagnosed with idiopathic pulmonary fibrosis. J Manag Care Spec Pharm. 2016;22:4.
31.
go back to reference Cao MS, Sheng J, Wang TZ, Qiu XH, Wang DM, Wang Y, et al. Acute exacerbation of idiopathic pulmonary fibrosis: usual interstitial pneumonitis vs. possible usual interstitial pneumonitis pattern. Chin Med J (Engl). 2019;132:18. Cao MS, Sheng J, Wang TZ, Qiu XH, Wang DM, Wang Y, et al. Acute exacerbation of idiopathic pulmonary fibrosis: usual interstitial pneumonitis vs. possible usual interstitial pneumonitis pattern. Chin Med J (Engl). 2019;132:18.
32.
go back to reference Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J. 2017;49:5.CrossRef Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J. 2017;49:5.CrossRef
33.
go back to reference Volm M, Mattern J, Stammler G. Up-regulation of heat shock protein 70 in adenocarcinomas of the lung in smokers. Anticancer Res. 1995;15:6b. Volm M, Mattern J, Stammler G. Up-regulation of heat shock protein 70 in adenocarcinomas of the lung in smokers. Anticancer Res. 1995;15:6b.
34.
go back to reference Roque W. Heat shock proteins in pulmonary fibrosis: pawns of cell homeostasis. Am J Physiology-Cell Physiol. 2022;322:6.CrossRef Roque W. Heat shock proteins in pulmonary fibrosis: pawns of cell homeostasis. Am J Physiology-Cell Physiol. 2022;322:6.CrossRef
35.
go back to reference Kono Y, Colley T, To M, Papaioannou AI, Mercado N, Baker JR, et al. Cigarette smoke-induced impairment of autophagy in macrophages increases galectin-8 and inflammation. Sci Rep. 2021;11:1.CrossRef Kono Y, Colley T, To M, Papaioannou AI, Mercado N, Baker JR, et al. Cigarette smoke-induced impairment of autophagy in macrophages increases galectin-8 and inflammation. Sci Rep. 2021;11:1.CrossRef
36.
go back to reference Kesireddy VS, Chillappagari S, Ahuja S, Knudsen L, Henneke I, Graumann J, et al. Susceptibility of microtubule-associated protein 1 light chain 3β (MAP1LC3B/LC3B) knockout mice to lung injury and fibrosis. Faseb j. 2019;33:11.CrossRef Kesireddy VS, Chillappagari S, Ahuja S, Knudsen L, Henneke I, Graumann J, et al. Susceptibility of microtubule-associated protein 1 light chain 3β (MAP1LC3B/LC3B) knockout mice to lung injury and fibrosis. Faseb j. 2019;33:11.CrossRef
37.
go back to reference Araya J, Kojima J, Takasaka N, Ito S, Fujii S, Hara H, et al. Insufficient autophagy in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2013;304:1.CrossRef Araya J, Kojima J, Takasaka N, Ito S, Fujii S, Hara H, et al. Insufficient autophagy in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2013;304:1.CrossRef
38.
go back to reference Wang K, Zhang T, Lei Y, Li X, Jiang J, Lan J, et al. Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux. Autophagy. 2018;14:2.CrossRef Wang K, Zhang T, Lei Y, Li X, Jiang J, Lan J, et al. Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux. Autophagy. 2018;14:2.CrossRef
39.
go back to reference Sathish V, Prakash YS. Sex differences in pulmonary anatomy and physiology. Implications for Health and Disease. In.; 2016. Sathish V, Prakash YS. Sex differences in pulmonary anatomy and physiology. Implications for Health and Disease. In.; 2016.
40.
go back to reference Sieminska A, Jassem E. The many faces of tobacco use among women. Med Sci Monit 2014;20. Sieminska A, Jassem E. The many faces of tobacco use among women. Med Sci Monit 2014;20.
41.
go back to reference Paul S, Amundson SA. Differential Effect of active smoking on Gene expression in male and female smokers. J Carcinog Mutagen 2014;5. Paul S, Amundson SA. Differential Effect of active smoking on Gene expression in male and female smokers. J Carcinog Mutagen 2014;5.
Metadata
Title
Smoking status and clinical outcome in idiopathic pulmonary fibrosis: a nationwide study
Authors
Hee-Young Yoon
Hoseob Kim
Yoonjong Bae
Jin Woo Song
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2024
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-024-02819-w

Other articles of this Issue 1/2024

Respiratory Research 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.